S&P 500   5,046.47 (+0.48%)
DOW   38,008.03 (+0.67%)
QQQ   427.70 (+0.44%)
AAPL   168.14 (+0.08%)
MSFT   411.11 (-0.18%)
META   510.32 (+3.27%)
GOOGL   156.25 (+0.50%)
AMZN   182.25 (+0.54%)
TSLA   151.69 (-2.42%)
NVDA   855.17 (+1.76%)
AMD   156.18 (+1.40%)
NIO   4.07 (+4.09%)
BABA   69.60 (+1.13%)
T   16.17 (+0.31%)
F   12.14 (+0.83%)
MU   115.47 (-0.74%)
GE   156.99 (+0.85%)
CGC   7.89 (+21.57%)
DIS   114.02 (+0.96%)
AMC   2.93 (-1.68%)
PFE   25.35 (-0.28%)
PYPL   62.95 (-0.49%)
XOM   119.06 (+0.36%)
S&P 500   5,046.47 (+0.48%)
DOW   38,008.03 (+0.67%)
QQQ   427.70 (+0.44%)
AAPL   168.14 (+0.08%)
MSFT   411.11 (-0.18%)
META   510.32 (+3.27%)
GOOGL   156.25 (+0.50%)
AMZN   182.25 (+0.54%)
TSLA   151.69 (-2.42%)
NVDA   855.17 (+1.76%)
AMD   156.18 (+1.40%)
NIO   4.07 (+4.09%)
BABA   69.60 (+1.13%)
T   16.17 (+0.31%)
F   12.14 (+0.83%)
MU   115.47 (-0.74%)
GE   156.99 (+0.85%)
CGC   7.89 (+21.57%)
DIS   114.02 (+0.96%)
AMC   2.93 (-1.68%)
PFE   25.35 (-0.28%)
PYPL   62.95 (-0.49%)
XOM   119.06 (+0.36%)
S&P 500   5,046.47 (+0.48%)
DOW   38,008.03 (+0.67%)
QQQ   427.70 (+0.44%)
AAPL   168.14 (+0.08%)
MSFT   411.11 (-0.18%)
META   510.32 (+3.27%)
GOOGL   156.25 (+0.50%)
AMZN   182.25 (+0.54%)
TSLA   151.69 (-2.42%)
NVDA   855.17 (+1.76%)
AMD   156.18 (+1.40%)
NIO   4.07 (+4.09%)
BABA   69.60 (+1.13%)
T   16.17 (+0.31%)
F   12.14 (+0.83%)
MU   115.47 (-0.74%)
GE   156.99 (+0.85%)
CGC   7.89 (+21.57%)
DIS   114.02 (+0.96%)
AMC   2.93 (-1.68%)
PFE   25.35 (-0.28%)
PYPL   62.95 (-0.49%)
XOM   119.06 (+0.36%)
S&P 500   5,046.47 (+0.48%)
DOW   38,008.03 (+0.67%)
QQQ   427.70 (+0.44%)
AAPL   168.14 (+0.08%)
MSFT   411.11 (-0.18%)
META   510.32 (+3.27%)
GOOGL   156.25 (+0.50%)
AMZN   182.25 (+0.54%)
TSLA   151.69 (-2.42%)
NVDA   855.17 (+1.76%)
AMD   156.18 (+1.40%)
NIO   4.07 (+4.09%)
BABA   69.60 (+1.13%)
T   16.17 (+0.31%)
F   12.14 (+0.83%)
MU   115.47 (-0.74%)
GE   156.99 (+0.85%)
CGC   7.89 (+21.57%)
DIS   114.02 (+0.96%)
AMC   2.93 (-1.68%)
PFE   25.35 (-0.28%)
PYPL   62.95 (-0.49%)
XOM   119.06 (+0.36%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$51.28
+0.2%
$53.26
$43.38
$62.88
$6.94B1.081.13 million shs137,405 shs
Haemonetics Co. stock logo
HAE
Haemonetics
$85.66
+0.9%
$78.72
$70.74
$95.26
$4.35B0.36437,633 shs39,629 shs
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$31.92
-0.1%
$37.32
$31.57
$59.10
$2.51B1.12639,960 shs154,751 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$10.59
-4.3%
$10.17
$3.89
$14.75
$247.49M1.11527,657 shs175,365 shs
Nevro Corp. stock logo
NVRO
Nevro
$12.27
-0.2%
$14.63
$12.12
$39.67
$450.06M0.89471,772 shs46,583 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
-1.18%-3.63%-0.91%-8.10%-11.38%
Haemonetics Co. stock logo
HAE
Haemonetics
+0.80%-1.50%+11.98%+1.65%-0.14%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
+0.38%-6.28%-6.72%-24.65%-44.71%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+14.89%-3.82%+3.26%-89.32%-91.28%
Nevro Corp. stock logo
NVRO
Nevro
-3.15%-7.59%-12.84%-32.25%-66.85%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.7487 of 5 stars
3.31.00.04.12.74.23.1
Haemonetics Co. stock logo
HAE
Haemonetics
3.9809 of 5 stars
2.34.00.04.32.31.71.9
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
4.6358 of 5 stars
3.15.00.04.00.91.73.1
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.8934 of 5 stars
3.32.00.04.60.00.00.6
Nevro Corp. stock logo
NVRO
Nevro
1.7445 of 5 stars
4.01.00.00.01.51.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.67
Moderate Buy$66.3329.36% Upside
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6722.19% Upside
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
2.22
Hold$44.8940.63% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.67
Moderate Buy$96.00806.52% Upside
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$21.2373.03% Upside

Current Analyst Ratings

Latest HAE, INO, GMED, NVRO, and IART Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Nevro Corp. stock logo
NVRO
Nevro
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00
4/12/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/11/2024
Nevro Corp. stock logo
NVRO
Nevro
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $16.00
4/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00
4/3/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$38.00
4/3/2024
Nevro Corp. stock logo
NVRO
Nevro
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00
3/18/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$60.00
3/7/2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform
3/1/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$46.00 ➝ $41.00
2/29/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$55.00 ➝ $49.00
2/22/2024
Nevro Corp. stock logo
NVRO
Nevro
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$23.00 ➝ $19.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.02B6.80$3.57 per share14.36$29.32 per share1.75
Haemonetics Co. stock logo
HAE
Haemonetics
$1.17B3.72$5.06 per share16.92$16.22 per share5.28
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$1.54B1.63$4.84 per share6.59$20.31 per share1.57
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$830K298.18N/AN/A$5.16 per share2.05
Nevro Corp. stock logo
NVRO
Nevro
$425.17M1.06N/AN/A$8.10 per share1.51

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$122.87M$1.1743.8315.631.527.83%8.82%7.20%5/7/2024 (Confirmed)
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4634.8220.301.999.97%22.37%9.71%5/9/2024 (Confirmed)
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$67.74M$0.8338.468.840.964.39%15.19%6.59%4/24/2024 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$7.56N/AN/AN/A-16,238.91%-79.86%-57.71%5/8/2024 (Estimated)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%4/24/2024 (Estimated)

Latest HAE, INO, GMED, NVRO, and IART Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
5/7/2024N/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.55N/A-$0.55N/AN/AN/A  
2/28/202412/31/2023
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.90$0.89-$0.01$1.53$399.30 million$397.00 million    
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million
2/20/2024Q4 2023
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.59$0.60+$0.01$1.09$608.21 million$616.53 million    
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.10
4.88
2.72
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
0.94
3.45
2.18
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.60
3.60
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
84.78%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Nevro Corp. stock logo
NVRO
Nevro
95.52%

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
24.30%
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3.10%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.90%
Nevro Corp. stock logo
NVRO
Nevro
3.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,000135.37 million102.48 millionOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3,94678.60 million76.17 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
12223.37 million22.93 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.58 millionOptionable

HAE, INO, GMED, NVRO, and IART Headlines

SourceHeadline
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
finance.yahoo.com - April 17 at 10:38 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
prnewswire.com - April 17 at 8:30 AM
Nevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of CanadaNevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of Canada
americanbankingnews.com - April 16 at 3:44 AM
Nevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of CanadaNevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of Canada
marketbeat.com - April 15 at 3:31 PM
Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00
americanbankingnews.com - April 13 at 5:32 AM
Nevro Corp. (NYSE:NVRO) Receives Consensus Rating of "Hold" from AnalystsNevro Corp. (NYSE:NVRO) Receives Consensus Rating of "Hold" from Analysts
americanbankingnews.com - April 12 at 2:34 AM
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by Analysts
marketbeat.com - April 12 at 2:33 AM
Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00
marketbeat.com - April 11 at 8:25 AM
Nevro (NYSE:NVRO) Trading Up 5.5%Nevro (NYSE:NVRO) Trading Up 5.5%
marketbeat.com - April 9 at 12:12 PM
Nevro (NYSE:NVRO) PT Lowered to $14.00 at Wells Fargo & CompanyNevro (NYSE:NVRO) PT Lowered to $14.00 at Wells Fargo & Company
americanbankingnews.com - April 9 at 4:56 AM
Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)
marketbeat.com - April 5 at 4:35 AM
Where Nevro Stands With AnalystsWhere Nevro Stands With Analysts
benzinga.com - April 3 at 1:52 PM
Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00
marketbeat.com - April 3 at 12:14 PM
Nevro (NYSE:NVRO) Stock Price Down 4.8%Nevro (NYSE:NVRO) Stock Price Down 4.8%
marketbeat.com - April 1 at 2:58 PM
EnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization
finanznachrichten.de - March 25 at 4:30 PM
Heres Why You Should Retain Nevro (NVRO) Stock for NowHere's Why You Should Retain Nevro (NVRO) Stock for Now
zacks.com - March 21 at 1:36 PM
Nevro Corp. (NYSE:NVRO) Given Consensus Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Consensus Rating of "Hold" by Analysts
marketbeat.com - March 18 at 2:40 AM
NVRO Mar 2024 20.000 putNVRO Mar 2024 20.000 put
finance.yahoo.com - March 11 at 12:27 AM
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral ScrewNevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
zacks.com - February 29 at 8:31 AM
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
prnewswire.com - February 28 at 4:10 PM
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
markets.businessinsider.com - February 27 at 1:07 AM
Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty
markets.businessinsider.com - February 26 at 7:38 AM
Nevro just downgraded at Oppenheimer, heres whyNevro just downgraded at Oppenheimer, here's why
realmoney.thestreet.com - February 23 at 2:42 AM
Nevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - February 22 at 9:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Globus Medical logo

Globus Medical

NYSE:GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Integra LifeSciences logo

Integra LifeSciences

NASDAQ:IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Inovio Pharmaceuticals logo

Inovio Pharmaceuticals

NASDAQ:INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.